Accepted for Publication: February 1, 2021.
Published Online: May 6, 2021. doi:10.1001/jamaoncol.2021.0580
Corresponding Author: Willemien J. van Driel, MD, PhD, Center for Gynecologic Oncology Amsterdam, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands (w.v.driel@nki.nl).
Author Contributions: Drs van Stein and van Driel had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: van Stein, Aalbers, Sonke.
Acquisition, analysis, or interpretation of data: van Stein, Aalbers, van Driel.
Drafting of the manuscript: van Stein, Aalbers.
Critical revision of the manuscript for important intellectual content: Aalbers, Sonke, van Driel.
Administrative, technical, or material support: van Stein, Aalbers.
Supervision: Aalbers, Sonke, van Driel.
Conflict of Interest Disclosures: Dr Sonke reported receiving institutional research support from AstraZeneca, Merck & Co, Inc, Novartis AG, and F. Hoffman–La Roche Ltd outside the scope of this review. No other disclosures were reported.
Additional Contributions: The Figure is reprinted with permission from LMC Vos, Netherlands Cancer Institute, all rights reserved.
4.Spratt
JS , Adcock
RA , Muskovin
M , Sherrill
W , McKeown
J . Clinical delivery system for intraperitoneal hyperthermic chemotherapy.
Cancer Res. 1980;40(2):256-260.
PubMedGoogle Scholar 5.Dedrick
RL , Myers
CE , Bungay
PM , DeVita
VT
Jr . Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Cancer Treat Rep. 1978;62(1):1-11.
PubMedGoogle Scholar 10.Sugarbaker
PH , Van der Speeten
K . Surgical technology and pharmacology of hyperthermic perioperative chemotherapy.
J Gastrointest Oncol. 2016;7(1):29-44.
PubMedGoogle Scholar 16.Los
G , Smals
OA , van Vugt
MJ ,
et al. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Cancer Res. 1992;52(5):1252-1258.
PubMedGoogle Scholar 17.van de Vaart
PJ , van der Vange
N , Zoetmulder
FA ,
et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
Eur J Cancer. 1998;34(1):148-154. doi:
10.1016/S0959-8049(97)00370-5
PubMedGoogle ScholarCrossref 19.Krawczyk
PM , Eppink
B , Essers
J ,
et al. Mild hyperthermia inhibits homologous recombination, induces
BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.
Proc Natl Acad Sci U S A. 2011;108(24):9851-9856. doi:
10.1073/pnas.1101053108
PubMedGoogle ScholarCrossref 23.Esquivel
J , Averbach
A . Laparoscopic cytoreductive surgery and HIPEC in patients with limited pseudomyxoma peritonei of appendiceal origin.
Gastroenterol Res Pract. 2012;2012:981245. doi:
10.1155/2012/981245
PubMedGoogle Scholar 24.Klaver
CEL , Wisselink
DD , Punt
CJA ,
et al; COLOPEC Collaborators Group. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.
Lancet Gastroenterol Hepatol. 2019;4(10):761-770. doi:
10.1016/S2468-1253(19)30239-0
PubMedGoogle ScholarCrossref 25.Bray
F , Ferlay
J , Soerjomataram
I , Siegel
RL , Torre
LA , Jemal
A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018;68(6):394-424. doi:
10.3322/caac.21492
PubMedGoogle ScholarCrossref 26.Timmermans
M , Sonke
GS , Van de Vijver
KK , van der Aa
MA , Kruitwagen
RFPM . No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands.
Eur J Cancer. 2018;88:31-37. doi:
10.1016/j.ejca.2017.10.030
PubMedGoogle ScholarCrossref 27.Doubeni
CA , Doubeni
AR , Myers
AE . Diagnosis and management of ovarian cancer.
Am Fam Physician. 2016;93(11):937-944.
PubMedGoogle Scholar 28.Vergote
I , Tropé
CG , Amant
F ,
et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
N Engl J Med. 2010;363(10):943-953. doi:
10.1056/NEJMoa0908806
PubMedGoogle ScholarCrossref 29.Wright
AA , Bohlke
K , Armstrong
DK ,
et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline.
J Clin Oncol. 2016;34(28):3460-3473. doi:
10.1200/JCO.2016.68.6907
PubMedGoogle ScholarCrossref 31.González-Martín
A , Pothuri
B , Vergote
I ,
et al; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer.
N Engl J Med. 2019;381(25):2391-2402. doi:
10.1056/NEJMoa1910962
PubMedGoogle ScholarCrossref 34.Tewari
D , Java
JJ , Salani
R ,
et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study.
J Clin Oncol. 2015;33(13):1460-1466. doi:
10.1200/JCO.2014.55.9898
PubMedGoogle ScholarCrossref 36.Walker
JL , Armstrong
DK , Huang
HQ ,
et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study.
Gynecol Oncol. 2006;100(1):27-32. doi:
10.1016/j.ygyno.2005.11.013
PubMedGoogle ScholarCrossref 37.Walker
JL , Brady
MF , Wenzel
L ,
et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group study.
J Clin Oncol. 2019;37(16):1380-1390. doi:
10.1200/JCO.18.01568
PubMedGoogle ScholarCrossref 39.Lim
MC , Chang
S-J , Yoo
HJ ,
et al. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer.
J Clin Oncol. 2017;35(15 suppl):5520. doi:
10.1200/JCO.2017.35.15_suppl.5520
Google Scholar 40.Zivanovic
O , Abramian
A , Kullmann
M ,
et al. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Int J Cancer. 2015;136(3):699-708.
PubMedGoogle Scholar 42.Koole
SN , Kieffer
JM , Sikorska
K ,
et al. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Eur J Surg Oncol. 2021;47(1):101-107. doi:
10.1016/j.ejso.2019.05.006
PubMedGoogle ScholarCrossref 43.Ceresoli
M , Verrengia
A , Montori
G ,
et al. Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study.
J Gynecol Oncol. 2018;29(3):e53. doi:
10.3802/jgo.2018.29.e53
PubMedGoogle Scholar 44.Koole
S , van Stein
R , Sikorska
K ,
et al; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Int J Gynecol Cancer. 2020;30(6):888-892. doi:
10.1136/ijgc-2020-001231
PubMedGoogle ScholarCrossref 45.Bois
AD , Sehouli
J , Vergote
I ,
et al Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20.
J Clin Oncol. 2020;38(15 suppl):6000. doi:
10.1200/JCO.2020.38.15_suppl.6000Google Scholar 47.Harter
P , Reuss
A , Sehouli
J , Chiva
L , du Bois
A . Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al.
Int J Gynecol Cancer. 2017;27(2):246-247. doi:
10.1097/IGC.0000000000000864
PubMedGoogle ScholarCrossref 52.Auer
RC , Sivajohanathan
D , Biagi
J , Conner
J , Kennedy
E , May
T . Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.
Curr Oncol. 2020;27(3):146-154. doi:
10.3747/co.27.6033PubMedGoogle ScholarCrossref 53.Hoppenot
C , Schuitevoerder
D , Izquierdo
FJ ,
et al; Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: management of ovarian neoplasms.
Ann Surg Oncol. 2020;27(6):1780-1787. doi:
10.1245/s10434-020-08322-y
PubMedGoogle Scholar 54.Colombo
N , Sessa
C , Bois
AD ,
et al; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Published online May 2, 2019.
Int J Gynecol Cancer. doi:10.1136/ijgc-2019-000308
PubMedGoogle Scholar 55.Koole
SN , van Lieshout
C , van Driel
WJ ,
et al. Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial.
J Clin Oncol. 2019;37(23):2041-2050. doi:
10.1200/JCO.19.00594
PubMedGoogle ScholarCrossref 56.Segelman
J , Granath
F , Holm
T , Machado
M , Mahteme
H , Martling
A . Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer.
Br J Surg. 2012;99(5):699-705. doi:
10.1002/bjs.8679
PubMedGoogle ScholarCrossref 57.Franko
J , Shi
Q , Meyers
JP ,
et al; Analysis and Research in Cancers of the Digestive System (ARCAD) Group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Lancet Oncol. 2016;17(12):1709-1719. doi:
10.1016/S1470-2045(16)30500-9
PubMedGoogle ScholarCrossref 58.Razenberg
LG , van Gestel
YR , Lemmens
VE , de Hingh
IH , Creemers
GJ . Bevacizumab in addition to palliative chemotherapy for patients with peritoneal carcinomatosis of colorectal origin: a nationwide population-based study.
Clin Colorectal Cancer. 2016;15(2):e41-e46. doi:
10.1016/j.clcc.2015.12.006
PubMedGoogle ScholarCrossref 59.Esquivel
J , Lowy
AM , Markman
M ,
et al. The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis.
Ann Surg Oncol. 2014;21(13):4195-4201. doi:
10.1245/s10434-014-3798-z
PubMedGoogle ScholarCrossref 60.Verwaal
VJ , van Ruth
S , de Bree
E ,
et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
J Clin Oncol. 2003;21(20):3737-3743. doi:
10.1200/JCO.2003.04.187
PubMedGoogle ScholarCrossref 62.Goéré
D , Glehen
O , Quenet
F ,
et al; BIG-RENAPE group. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (ProphyloCHIP-PRODIGE 15): a randomised, phase 3 study.
Lancet Oncol. 2020;21(9):1147-1154. doi:
10.1016/S1470-2045(20)30322-3
PubMedGoogle ScholarCrossref 63.ClinicalTrials.gov. Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma (HIPECT4). NCT02614534. Accessed February 1, 2021.
https://clinicaltrials.gov/ct2/show/NCT02614534 65.Klaver
CE , Groenen
H , Morton
DG , Laurberg
S , Bemelman
WA , Tanis
PJ ; research committee of the European Society of Coloproctology. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines.
Colorectal Dis. 2017;19(3):224-236. doi:
10.1111/codi.13593
PubMedGoogle ScholarCrossref 66.Bushati
M , Rovers
KP , Sommariva
A ,
et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).
Eur J Surg Oncol. 2018;44(12):1942-1948. doi:
10.1016/j.ejso.2018.07.003
PubMedGoogle ScholarCrossref 67.Quénet
F , Elias
D , Roca
L ,
et al; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol. 2021;22(2):256-266. doi:
10.1016/S1470-2045(20)30599-4
PubMedGoogle ScholarCrossref 68.Rovers
KP , Bakkers
C , Simkens
GAAM ,
et al; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
BMC Cancer. 2019;19(1):390. doi:
10.1186/s12885-019-5545-0
PubMedGoogle ScholarCrossref 69.Nagourney
RA , Evans
S , Tran
PH , Nagourney
AJ , Sugarbaker
PH . Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin. Published online September 19, 2020.
Eur J Surg Oncol. doi:
10.1016/j.ejso.2020.09.017
PubMedGoogle Scholar 70.Hompes
D , D’Hoore
A , Wolthuis
A ,
et al. The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
J Surg Oncol. 2014;109(6):527-532. doi:
10.1002/jso.23546
PubMedGoogle ScholarCrossref 71.van Eden
WJ , Kok
NFM , Woensdregt
K , Huitema
ADR , Boot
H , Aalbers
AGJ . Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
Eur J Surg Oncol. 2018;44(2):220-227. doi:
10.1016/j.ejso.2017.10.216
PubMedGoogle ScholarCrossref 72.Prada-Villaverde
A , Esquivel
J , Lowy
AM ,
et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
J Surg Oncol. 2014;110(7):779-785. doi:
10.1002/jso.23728
PubMedGoogle ScholarCrossref 74.Bakkers
C , van Erning
FN , Rovers
KP ,
et al. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study.
Eur J Surg Oncol. 2020;46(10, pt A):1902-1907. doi:
10.1016/j.ejso.2020.04.018
PubMedGoogle ScholarCrossref 75.Ubink
I , Bolhaqueiro
ACF , Elias
SG ,
et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
Br J Surg. 2019;106(10):1404-1414. doi:
10.1002/bjs.11206
PubMedGoogle ScholarCrossref 76.Goéré
D , Souadka
A , Faron
M ,
et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study.
Ann Surg Oncol. 2015;22(9):2958-2964. doi:
10.1245/s10434-015-4387-5
PubMedGoogle ScholarCrossref 77.Kwakman
R , Schrama
AM , van Olmen
JP ,
et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis.
Ann Surg. 2016;263(6):1102-1111. doi:
10.1097/SLA.0000000000001593
PubMedGoogle ScholarCrossref 78.Ubink
I , van Eden
WJ , Snaebjornsson
P ,
et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.
Br J Surg. 2018;105(2):e204-e211. doi:
10.1002/bjs.10788
PubMedGoogle ScholarCrossref